Background
==========

Epidermal growth factor receptor (EGFR), which participates in signaling pathways that are deregulated in cancer cells, is a promising target in epithelial cancer, notably colorectal cancer \[[@B1]\]. Cetuximab (Erbitux^®^), a monoclonal antibody targeting EGFR, is currently used in EGFR-expressing metastatic colorectal cancer (mCRC) in combination with cytotoxic chemotherapy (irinotecan), after failure of a previous irinotecan-based regimen. In this setting, cetuximab produces objective response in about 25% of patients, with nearly 30% of patients achieving disease stabilization \[[@B2]\], resulting in a median progression-free survival of 4 months and a median overall survival of 6 to 9 months. Recently, another EGFR-targeted monoclonal antibody, panitumumab (vectibix^®^) was FDA-approved in mCRC as single agent, after failing chemotherapy drugs fluoropyrimidine, oxaliplatin and irinotecan\[[@B3]\]. Panitumumab induces a response rate of 10%, similar to that achieved with single-agent cetuximab in a similar patient population \[[@B4],[@B5]\], and demonstrates a modest but significant increase in median progression-free survival against best supportive care.

Clearly, clinical benefit with EGFR-targeting antibodies seems to be restricted to a particular subgroup of mCRC patients. However, no validated predictive factor is currently available to improve the rational administration of these therapies in this patient population. Such factors are critically needed, especially if we consider the high cost of these new therapeutics\[[@B6]\] and their expected future integration in regimens administered in earlier clinical stages, including first-line treatment of mCRC and adjuvant chemotherapy in stage III localized disease.

Somatic mutations of EGFR tyrosine kinase domain are associated with exquisite sensitivity to EGFR-tyrosine kinase inhibitors erlotinib and gefitinib in non-small cell lung cancer (NSCLC) \[[@B7]-[@B9]\], but such mutations are rare or absent in CRC \[[@B5],[@B10]\]. EGFR protein expression, as evaluated by immunohistochemistry, does not correlate with response \[[@B2],[@B4],[@B11]\] and only specific treatment-induced skin rash seems associated with tumor response and progression-free survival \[[@B2]\].

Recent retrospective data have suggested that *EGFR*amplification or *KRAS*exon 1 somatic mutations may allow a better selection of patients who are candidates for EGFR targeting \[[@B12],[@B13]\]. In a first study \[[@B12]\], an increase in *EGFR*copy number identified by FISH (fluorescence in situ hybridization) was found in all but one responding patients, while four recent studies identified no or few cetuximab responders in *KRAS*mutated patients \[[@B13]-[@B17]\].

In the present retrospective study of 32 patients with EGFR-positive mCRC treated with cetuximab-based combination, we have analyzed *EGFR*copy number by FISH and sequenced the extracellular domains (ECD) of *EGFR*, as well as *KRAS*exon 1, and correlated these data with clinical outcome.

Methods
=======

Patients and treatment
----------------------

We retrospectively assessed 32 patients with EGFR-positive mCRC treated with cetuximab-irinotecan combination at the Institut PAOLI-CALMETTES, Marseille, France between March 2004 and July 2005 who were evaluable for tumor response and had available pre-treatment frozen and/or formalin-fixed and paraffin-embedded tumor tissues (from primary and/or metastatic tumor tissue). EGFR positivity was defined by at least 1% malignant cells demonstrating EGFR immunostaining (antibody from Zymed Laboratories, Inc., San Francisco, 1/20, digested with pepsin). In 26 patients, cetuximab was used according to official registration in irinotecan-resistant patients and administered as a loading dose of 400 mg/m2 intravenously, followed by 250 mg/m2 once a week until progression, in combination with irinotecan 180 mg/m^2^every other week. In addition, 6 patients received cetuximab/irinotecan in specific clinical trials evaluating:

\- a dose escalation of cetuximab in irinotecan-resistant patients (n = 3)

\- cetuximab in combination with Folfiri as first-line treatment (n = 2) or as second-line treatment after failure of first-line fluoropyrimidine/oxaliplatin (n = 1).

Tumor evaluation was performed with appropriate methods within four weeks of treatment initiation and repeated during treatment every 2 months for the first 6 months and then every 3 months until disease progression. WHO criteria of response were used \[[@B18]\]. Briefly, the sum of products of target lesions was calculated and response was determined as follows: complete response (CR), disappearance of all target lesions without any residual lesion; partial response (PR), 50% or more decrease in target lesions; progressive disease (PD), 25% or more increase in the size of measurable lesions or appearance of new lesions; stable disease (SD), neither PR or PD criteria are met. This study was approved by an institutional review board and patient consent for analysis of stored biological samples, in relation with clinical data including imagery data, was verified for all patients included.

EGFR copy number by FISH
------------------------

Formalin-fixed paraffin-embedded (FFPE) tissue sections (5 μm) were placed in pretreatment solution for 60 min at 80°C, and digested with pepsin solution for 15 min at 37°C. Dual-color, dual-target FISH assays were done with the SPEC EGFR/CEN7 Dual Color Probe Kit (ZytoVision, Bremerhaven, Germany). Tissue sections, covered with 10-μL probe solution, were incubated at 75°C for 10 min to co-denature EGFR and CEN7 (chromosome seven α-centromeric) probes and allowed to hybridize overnight at 37°C. Codenaturation and hybridization were done sequentially in a microprocessor-controlled system (Hybridizer, DakoCytomation, Glostrup, Denmark). Posthybridization stringency wash was done in a water bath at 37°C for 5 min. After washing 4 times and drying at room temperature for 15 min, tissue sections were covered with 4\'-6-diamidino-2-phenylindole (DAPI/Antifade Solution, ZytoVision, Bremerhaven, Germany) for chromatin counterstaining before microscopy. Sample material was evaluated by fluorescence microscopy (Leica. DM RXA). Filter sets for the following wavelength ranges were required: EGFR (ZyGreen), excitation at 503 nm and emission at 528 nm, similar to FITC; chromosome 7 (ZyOrange), excitation at 547 nm and emission at 572 nm, similar to Rhodamine.

Two independent observers (SE and AL) scored at least 100 non-overlapping interphase nuclei for the number of copies of EGFR and CEN7 by use of predefined scoring guidelines. The negative controls consisted of a healthy colorectal mucosa adjacent to malignant disease; the control for amplified EGFR was an amplified colonic adenocarcinoma. FISH patterns were defined as described in \[[@B19]\] : Briefly, the samples were grouped as follows: normal disomy, two gene copies in more than 90% of cells; trisomy, three gene copies in more than 10% of cells and ratio gene/chromosomes ≤ 2 ; low polysomy, at least four gene copies in more than 10% but fewer than 40% of cells and ratio gene/chromosomes ≤ 2; high polysomy, at least four gene copies in more than 40% cells and ratio gene/chromosomes ≤ 2; and gene amplification, ratio gene/chromosome more than two or 15 gene copies in at least 10% of cells. Trisomy and low polysomy were not considered as increases in *EGFR*copy number. Tumors showing high polysomy and/or gene amplification were considered to be FISH positive and as significant increases in *EGFR*copy number.

DNA extraction and mutation analyses
------------------------------------

DNA was extracted from frozen (n = 20) or FFPE colorectal cancer samples (n = 12) with the QIAamp DNA minikit (Qiagen). For FFPE tissues, samples were obtained by pinching tissue fragments within a tumor zone under microscopic control. Exon 1 of KRAS, the site of the most frequent activating mutations in codons 12 and 13, and exons 6 to 14 of EGFR, corresponding to the transmembrane and extracellular domains, were sequenced after PCR amplification of each exon using the BigDye terminator kit v1.1 (Applied Biosystems) and the PhredPhrapConsed package. Genotypes were assessed with the GeneMapper software (Applied Biosystems).

Statistical analyses
--------------------

Fischer\'s exact test was used to calculate p-values for the association between genetic parameters and response to cetuximab. Progression-free survival (PFS) was calculated from the date of cetuximab initiation to the date of disease progression, date of death if it occurred before progression, or date of last news. Overall survival (OS) was calculated from the date of cetuximab initiation to the date of death or the date of last news. Survivals were estimated with the Kaplan-Meier method. Survival curves were compared using the log-rank test. Analysis was carried out using the R software. The level of significance was set at p = 0.05.

Results
=======

Patient population
------------------

Patient characteristics are summarized in table [1](#T1){ref-type="table"}. Cetuximab was administered after failing 2 or more regimens in 22 patients. Twenty-four patients had been previously exposed to fluoropyrimidines, irinotecan and oxaliplatin. Median follow-up was 19.1 months. An objective response was observed in 9 patients (RR = 28%; CI95%, 15--45%), and 12 patients experienced stable disease, which lasted 6 months or more for 2 patients. Eleven patients progressed at the first evaluation. Median progression-free and overall survivals were 4.1 months (CI95%, 3.6--6.3) and 17.2 months (CI95%, 13.8-NR), respectively.

###### 

Patient population

                                   Patients   
  -------------------------------- ---------- ------------
  Characteristics                  number     percentage
                                              
  All patients                     16         
  Sex                                         
  Male                             16         50%
  Female                           16         50%
  Age, years                                  
  Median                                      58
  Range                                       36--78
  Tumor site                                  
  Colon                            21         65%
  Rectum                           11         35%
  Previous adjuvant chemotherapy              
  Yes                              10         31%
  No                               22         69%
  Line of cetuximab use                       
  Median                                      3
  Range                                       1--5
  Response status                             
  CR                               0          
  PR                               9          28.1%
  SD                               12         37.5%
  PD                               11         34.4%

CR = Complete response, PR = Partial response, SD = Stable disease and PD = Progressive disease were defined as described in the methods section.

EGFR copy numer analysis
------------------------

No authentic regional amplification was observed. An increased *EGFR*copy number was noted in 12 patients (Table [2](#T2){ref-type="table"}), but was considered as significant in only 2 patients, corresponding to high polysomy (patients 1 and 3, Figure [1](#F1){ref-type="fig"}). Both patients responded to cetuximab.

###### 

Molecular Alterations in tumors of metastatic colorectal cancer patients

  Pt number              Sex   Age   Previous adjuvant CT   Type of adjuvant CT   Previous regimen for metastatic disease   Tumor Best response   Time to progression (weeks)   *KRAS*exon 1   *EGFR*exon13   *EGFR copy Number (FISH)*
  ---------------------- ----- ----- ---------------------- --------------------- ----------------------------------------- --------------------- ----------------------------- -------------- -------------- ---------------------------
  ***Responders***                                                                                                                                                                                            
  1                      F     70    0                                            \-                                        PR                    10                            Wild-type      R521K          high polysomy
  2                      M     62    0                                            Folfirinox                                PR                    94\*                          Wild-type                     trisomy
  3                      F     56    0                                            Folfiri, Folfox                           PR                    9                             Wild-type                     high polysomy
  4                      M     37    0                                            Folfiri, Folfox, xelox                    PR                    44                            Wild-type                     low polysomy
  5                      F     44    0                                            Folfiri, Folfiri                          PR                    33                            Wild-type      R521K          disomy
  6                      F     54    1                      LV5FU                 Folfiri                                   PR                    67                            Gly13Asp                      disomy
  7                      F     52    1                      Fufol                 Folfirinox, Folfiri, LV5FU-mitomycine     PR                    42                            Gly12Asp       R521K          disomy
  8                      M     56    0                                            Foflfox                                   PR                    25                            Wild-type                     disomy
  9                      M     66    1                      Fufol                 Folfiri, Folfox                           PR                    24\*                          Wild-type      R521K          trisomy
                                                                                                                                                                                                              
  ***Non-responders***                                                                                                                                                                                        
  10                     F     68    0                                            Folfiri, Xeloda, Xelox                    SD                    17                            Wild-type      R521K          trisomy
  11                     F     74    1                      LV5FU                 Folfiri                                   SD                    10                            Gly12Val                      disomy
  12                     M     61    0                                            Folfirinox                                SD                    18                            Gly13Asp       R521K          disomy
  13                     F     71    0                                            Xelox Avastin-Xeliri                      SD                    15                            Gly12Asp                      disomy
  14                     M     59    0                                            LV5FU, Folfiri, Folfox                    SD                    24                            Gly12Cys       R521K          trisomy
  15                     M     71    0                                            Folfox, Irinotecan                        SD                    14                            Wild-type                     disomy
  16                     F     60    1                      Fufol                 Folfiri, Folfox, Cape, LV5FU              SD                    17                            Wild-type                     trisomy
  17                     M     65    0                                            Folfirinox, Folfiri                       SD                    18                            Wild-type                     low polysomy
  18                     M     66    0                                            Folfiri                                   SD                    17                            Wild-type      R521K          disomy
  19                     F     45    0                                            Folfox, Xelox                             SD                    17                            Wild-type      R521K          NE
  20                     F     42    0                                            Folfirinox                                SD                    21                            Gly12Asp       R521K          trisomy
  21                     M     62    1                      Folfox                Xeliri                                    SD                    36                            Gly13Asp       R521K          disomy
  22                     M     58    1                      Folfiri               Xelox, Xeliri                             PD                    NA                            Gly13Asp                      disomy
  23                     M     75    1                      Xelox                 Xeliri                                    PD                    NA                            Wild-type                     trisomy
  24                     M     81    0                                            Xelox, Folfiri                            PD                    NA                            Gly12Val                      disomy
  25                     F     55    0                                            Xelox Avastin-Xeliri                      PD                    NA                            Gly12Asp                      disomy
  26                     M     60    1                      LV5FU                 Folfiri, Folfiri, Folfox                  PD                    NA                            Wild-type                     NE
  27                     M     59    0                                            Folfiri, Folfiri/Folfox, Folfox           PD                    NA                            Gly12Asp                      NE
  28                     F     58    1                      LV5FU                 Folfiri, Xelox                            PD                    NA                            Gly12Asp                      disomy
  29                     M     51    0                                            Folfox, Folfiri                           PD                    NA                            Wild-type                     disomy
  30                     F     66    0                                            Folfiri, Xelox                            PD                    NA                            Wild-type      R521K          trisomy
  31                     F     56    0                                            \-                                        PD                    NA                            Wild-type                     disomy
  32                     F     78    0                                            Folfox, Folfiri, Cape                     PD                    NA                            Gly12Val                      disomy

F = female, M = Male, Folfox = oxaliplatin, fluorouracil, and folinic acid; Xelox = capecitabine, oxaliplatin; Folfiri = irinotecan, fluorouracil, and folinic acid; Xeliri = Capecitabine, irinotecan; Folfirinox = oxaliplatin, irinotecan, fluorouracil, and folinic acid; LV5FU = infusional FU and folinic acid; Fufol = bolus fluorouracil and folinic acid; PR = partial response. SD = stable disease. PD = progressive disease. R521K = point substitution G→A on exon 13 *EGFR*resulting in the amino acid substitution Arg to Lys in position 521. NA = not applicable. NE = not evaluable.

![**Dual color FISH assays for probes of EGFR (green) and chromosome seven (CEP7, red)**. (A) Balanced disomy in healthy colorectal mucosa. (B) Balanced disomy in tumor of patient 15. (C) Balanced low polysomy in tumor of patient 4. (D) High polysomy in tumor of patient 1. (E) Amplification in a control tumor.](1471-2407-8-169-1){#F1}

EGFR sequencing
---------------

We sequenced *EGFR*exons 6 to 14 coding for the transmembrane and extracellular domains. No mutation was found, but a heterozygous (9 patients) or homozygous (3 patients) point substitution G→A on exon 13, resulting in the amino acid substitution of arginine by lysine in position 521 (R521K), was detected in 12 patients. This variant was observed in 11 of 21 patients achieving objective response (4 patients) or stable disease (7 patients) and in 1 of 11 patients with rapidly progressive disease (defined as progression at time of the first evaluation) (p = 0.02, Fischer\'s exact test) (Table [2](#T2){ref-type="table"}). As shown in figure [2A](#F2){ref-type="fig"}, median PFS and OS were significantly better in patients with the R521K variant than in wild-type patients (5.7 \[CI95%, 4.3-NR\] vs. 3.2 \[CI95%, 2.5--4.7\] months; p = 0.041, log-rank test for PFS; 20.1 \[CI95%, 16-NR\] vs. 13.8 \[CI95%, 7.7-NR\] months; p = 0.03 log-rank for OS).

![**Survivals according to *EGFR*and *KRAS*genotypes**. A/ Progression-free survival (PFS) (Left) and overall survival (OS) (Right) curves of patients with *EGFR*R521K variant and wild-type. B/ PFS (Left) and OS (Right) curves of patients with a *KRAS*-mutated and nonmutated tumor.](1471-2407-8-169-2){#F2}

KRAS mutations
--------------

Sequencing of *KRAS*exon 1 was performed and correlated with clinical outcome (Table [2](#T2){ref-type="table"}). Fourteen patients displayed *KRAS*exon 1 mutations (codon 12 for 10 patients, codon 13 for 4 patients). Of the 32 genotyped tumors, 19 were metastases and 13 were primary tumors. In six patients, paired primary and metastatic tumors were available; no discordance was observed between the genotypes. In 9 responding patients, 2 had a *KRAS*mutation (22%), whereas 12 of 23 (52%) nonresponding patients had a *KRAS*mutation. This difference was not statistically significant (p = 0.234, Fischer\'s exact test). As shown in figure [2B](#F2){ref-type="fig"}, PFS was similar in *KRAS*-nonmutated and *KRAS*-mutated patients: median PFS was 3.9 months (CI 95%, 2.5--11) and 4.7 months (CI 95%, 2.7--11.3) (p = 0.968, log-rank test) in *KRAS*-nonmutated and *KRAS*-mutated patients, respectively. Overall survival was better in *KRAS*-nonmutated (20.8 months \[CI 95%, 14.5-NR\]) than in *KRAS*-mutated patients (13.8 months \[CI 95%, 11.5-NR\]), however this difference did not reach statistical significance (p = 0.472, log-rank test).

Clinical features of KRAS-mutated benefiting from cetuximab based-treatment
---------------------------------------------------------------------------

To better examine the clinical relevance of response or long-lasting stable disease obtained by cetuximab-irinotecan combination in 3 patients with KRAS-mutated tumors, their medical records were reviewed. The first patient (Pt 6) was a 53-year-old woman presenting liver metastases from a primary pT2N2 colon cancer resected in May 2003. She had received adjuvant LV-5FU (infusional 5FU/folinic acid) chemotherapy between May 2002 and October 2003. A first hepatic relapse occurred in January 2004 and was treated with two courses of Folfox (5FU, folinic acid, oxaliplatin) followed by Folfiri (5FU, folinic acid, irinotecan) due to allergic reaction after oxaliplatin infusion. The patient achieved a partial response and a right hepatectomy for metastasis removal was performed on April 2004, followed by six cycles of Folfiri in August 2004. She had a second hepatic relapse in September 2004 and in October 2004 was subjected to radiofrequency ablation which failed, resulting in the appearance of an additional hepatic lesion. The patient started cetuximab in association with irinotecan in January 2005 and achieved an authentic partial response allowing surgical removal in April 2005 (Figure [3A](#F3){ref-type="fig"}). Surgery was pathologically complete and the patient was alive in complete remission at time of last news in May 2006.

![**Objective partial responses to cetuximab-based treatment in patients with *KRAS-*mutated tumors**. (A) Pre- and post-cetuximab CT scan showing partial tumor response allowing surgical resection to be performed in patient 6. (B) Pre- and post-cetuximab CT scan demonstrating a major tumor response to cetuximab-based treatment in patient 7.](1471-2407-8-169-3){#F3}

The second responding patient with a *KRAS*mutation (Pt 7) was a 52-year-old woman who had been treated in June 1999 for a primary adenocarcinoma of the rectum classified pT4N2. The patient received post-operative radio-chemotherapy with Fufol (Bolus 5FU/folinic acid) on week 1 and 5. In February 2000, she had liver metastases that were completely surgically removed. In December 2000, she had a second hepatic relapse and received an association of 5FU/irinotecan/oxaliplatin for 2 months allowing her to be a candidate for a second complete surgical removal which was performed in April 2001. On January 2003, she experienced a third relapse involving retroperitoneal lymph nodes which was treated with Folfiri until May 2003, when a partial response was achieved. Maintenance with capecitabine was initiated and continued until October 2003 when disease progressed on both lymph nodes and the liver. A palliative treatment was started combining 5FU and mitomycin C with no response. The patient started cetuximab with irinotecan in March 2004, when the compound became available in France. She experienced a partial response until January 2005 (Figure [3B](#F3){ref-type="fig"}), when she developed bone metastases with spinal compression. She died in February 2005.

Finally, a third patient (pt 21) with a *KRAS*mutation achieved long-lasting stable disease (8 months), under cetuximab-irinotecan treatment. This 62-year old man had been treated in 2004 for a pT3N2 colon cancer by surgery followed by adjuvant Folfox. In December 2004, while he was receiving Folfox, he developed liver metastases which were surgically removed. Post-operative treatment was initiated in March 2005 with an association of capecitabine/irinotecan, but lung metastases occurred under treatment. A combination of cetuximab and irinotecan was started in June 2005 and continued with stable disease until February 2006 when peritoneal and lung progression occurred. The patient died in August 2006.

Discussion
==========

In this retrospective and preliminary study including 32 mCRC patients receiving cetuximab-based treatment, we have analyzed molecular factors that have been suggested to regulate activity of EGFR-targeted approaches.

EGFR copy number
----------------

Using a FISH-based assay, we evaluated *EGFR*copy number and did not observe any *EGFR*amplification (ratio *EGFR*to Control probes \>2 or ≥ 15 gene copies in ≥ 10% of cells), although trisomy or polysomy was observed in 12 patients. Only 2 patients displayed an increase in *EGFR*copy number that reached the definition of high polysomy (≥ four gene copies in ≥ 40% cells). However, these 2 patients were objective responders to cetuximab. In previous studies, an increase in *EGFR*gene copy number has been observed in 0.6 to 31% of CRC. These variations may be due in part to the techniques used to evaluate amplification, which include FISH, CISH or real-time quantitative PCR. Moreover, amplifications limited to the *EGFR*locus must be distinguished from extracopies of the entire chromosome 7 which contains the *EGFR*gene (polysomy). In a study involving 31 patients\[[@B12]\], Moroni et al observed an increase in *EGFR*copy number in 8 of the 9 cetuximab-responders but only in 1 of the 20 nonresponder patients who were assessable by FISH, suggesting that this increase may represent a strong positive predictive factor for response to this compound. Of note, an authentic amplification was found in 7 of these 9 patients with increased *EGFR*copy number. However, the same group recently reported no actual *EGFR*amplification but only polysomy in 58 FISH-analyzed tumors from mCRC patients receiving panitumumab. These authors have concluded that the previously observed amplification frequency could have been overestimated by scoring as amplified some tumors with only very limited foci of amplification. Nevertheless, this study still suggested a significant association between *EGFR*copy number and response and survival \[[@B20]\]. Other groups have reported a lower rate of copy gain, corresponding most often to polysomy \[[@B13],[@B21]-[@B23]\]. In one of these studies which is consistent with our own results, only 3 patients out of 30 displayed an increase in *EGFR*copies as evaluated by CISH \[[@B13]\]; these 3 patients responded to cetuximab. Thus, a significant increase in *EGFR*copy number may be associated with a high probability of response, even though this molecular alteration may be relatively rare in mCRC. Furthermore, regarding the significant number of responding patients without any significant increase in *EGFR*copy number in both Lievre et al\'s study (8 out of 11 responders) and ours (7 out of 9 responders), we do not believe that this parameter should be considered as a prerequisite for cetuximab activity.

KRAS mutations
--------------

Recent retrospective data from several independent studies have shown a very negative association between *KRAS*exon 1 mutations and cetuximab response in mCRC patients. A first group found no *KRAS*mutations in tumors from 11 cetuximab-responding patients, whereas 13 of the 19 nonresponders (p = 0.0003) had a *KRAS*-mutated tumor, leading the authors to suggest that *KRAS*mutational status could serve to exclude cetuximab use in mCRC\[[@B13]\]. A second recently published study involving 59 refractory mCRC patients receiving cetuximab-based treatment confirmed these data by reporting no mutations in all 12 responding patients, with a significantly worse time-to-progression in patients with a *KRAS*mutation\[[@B14]\]. Additionally, a third report has shown that mutations affecting either *KRAS*or *BRAF*are predictive and prognostic indicators in mCRC patients, and are inversely correlated with response to anti-EGFR monoclonal antibodies \[[@B16]\]. Another study evaluating *KRAS/BRAF*mutation status in 80 patients receiving cetuximab as single-agent found only 3 *KRAS*mutated tumors out of 27 patients who experienced a clinical benefit, but 27 out of 53 nonresponding patients \[[@B15]\]. Finally, recent data from 27 mCRC patients observed only one responder out of 10 mutated tumors compared to 9 out of 17 non mutated tumors\[[@B17]\]. We found a similar trend in our study, although our observations did not reach statistical significance. Moreover, pooling all published studies evaluating this putative association further suggests that *KRAS*mutations strongly negatively affect the probability of objective response to cetuximab treatment. In these studies, the response rate in *KRAS*mutated tumors was 9 out of 115 (7.8%, CI95%: 3.6--14.3%) versus 81 out of 192 (42.2%, CI95%: 35.1--49.5%) in wild type tumors (p = 3.5 10^-10^, chi-2 test). However, we did not find any statistically significant difference in OS or PFS in patients with KRAS-mutated and wild-type tumors. Although this lack of difference may be reasonably attributed to the limited sample size, data presented in our study also demonstrated that authentic and clinically relevant tumor responses and/or long-term stabilization may be achieved with cetuximab-based treatment in patients with *KRAS*-mutated tumors. Accordingly, we believe that it could be premature to absolutely exclude cetuximab use in these patients.

A variant of EGFR extracellular region
--------------------------------------

Activating mutations of the intracellular kinase domain of *EGFR*have been associated with human malignancies and responsiveness to small molecule EGFR tyrosine kinase inhibitors\[[@B5],[@B10],[@B12]\]. These mutations are rare or absent in mCRC, and are thus unlikely to explain the reported antitumor activity of cetuximab in this population. Nevertheless, little is known about the extracellular region of EGFR which represents the binding site of cetuximab. We sequenced this entire domain and did not find any mutations. However, we observed in 12 patients (37%) a G→A substitution in exon 13, which encodes a part of the extracellular region of the receptor. The resulting amino acid substitution Arg to Lys is located at the boundary between EGFR domain III, which represents the direct interaction site with cetuximab, and domain IV \[[@B24]\]. In our study, this variation was observed in 11 patients achieving at least a stable disease as their best response, but only in 1 patient with progressive disease at its first evaluation. Moreover, PFS and OS after cetuximab treatment were significantly better in the subset of patients displaying this variant.

This substitution, considered as a polymorphism (rs11543848 in SNPdb, heterozygosity of 0.41), may be relatively conservative, as both Arg and Lys are positively charged amino acids with similar side chains. It is also found in DNA from normal human lymphocytes \[[@B25]\] obtained from individuals without malignant diseases with a frequency of about 20% (homozygous variant) to 50% (heterozygous variant) in the general population \[[@B26]\].

Furthermore, *EGFR*exon 13 R521K variant has been already described in other EGFR expressing tumors, such as gliomas and lung cancer \[[@B27]\]. This *EGFR*polymorphism, previously described as codon 497 (R497K) according to an older nomenclature, has been negatively associated with pelvic recurrence in patients with rectal cancer treated with chemoradiation \[[@B28]\]. Recent data have shown that it correlates with a decrease in EGFR phosphorylation, decreased invasion, lower nodal involvement, reduced subsequent metastasis, and longer disease-free and overall survival in stage II/III colorectal carcinoma patients who have received curative surgery\[[@B26]\]. In addition, R521K was associated with oxaliplatin/FU efficacy in metastatic patients. Interestingly, the resulting amino acid substitution (Arg to Lys) was shown to significantly reduce TGFα binding and ligand-induced EGFR signaling \[[@B29]\]. Thus, it is tempting to speculate that *EGFR*variant may alter binding of its specific ligands leading to a particular phenotype of EGFR signaling. This is particularly interesting in light of very recent evidences generated from a microarray study showing that expression of EGFR ligands epiregulin and amphiregulin may predict cetuximab benefit \[[@B15]\]. An attenuated EGFR-mediated signaling, as putatively supposed with R521K polymorphism, could be even more sensitive to targeted receptor inhibition. Alternatively, R521K variant could also affect drug binding and/or effects. However, such preliminary hypotheses remain to be proven: we have initiated specific functional studies evaluating the correlation between cetuximab sensitivity and the *EGFR*exon 13 genotype in various CRC cell lines and in cellular models expressing wild type *EGFR*or the *EGFR*R521K variant. Importantly, EGFR genotyping on a larger cohort of cetuximab-treated patients, the accrual of which is currently ongoing, will be essential to confirm our findings.

Conclusion
==========

In conclusion, genetic factors affecting cetuximab response are likely to be multiple. *EGFR*copy number as well as variations in amino acid composition of the extracellular region may favorably impact cetuximab activity, whereas *KRAS*mutations negatively alter the probability of response, without totally abolishing it. However, these data from a small-sized patient population are still preliminary. Thus, validation of these results on larger cohorts and prospective studies are imperatively needed.
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